Literature DB >> 20971113

Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries.

Charlene A Wong1, Mona Saraiya, Susan Hariri, Linda Eckert, Roberta I Howlett, Lauri E Markowitz, Julia M L Brotherton, Katy Sinka, Olga G Martinez-Montañez, Susanne K Kjaer, Eileen F Dunne.   

Abstract

In this review, we describe plans to monitor the impact of human papillomavirus (HPV) vaccine on biologic outcomes in selected international areas (Australia, Canada, Mexico, the Nordic countries, Scotland, and the United States) that have adopted this vaccine. This summary of monitoring plans provides a background for discussing the challenges of vaccine monitoring in settings where resources and capacity may vary. A variety of approaches that depend on existing infrastructure and resources are planned or underway for monitoring HPV vaccine impact. Monitoring HPV vaccine impact on biologic outcomes is a complex and challenging task, but also plays an important role in documenting the benefit of vaccination, monitoring the progress of vaccination programs, and providing data to inform vaccination and disease prevention policies. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20971113     DOI: 10.1016/j.vaccine.2010.10.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010-2016.

Authors:  Laura M Mann; Eloisa Llata; Elaine W Flagg; Jaeyoung Hong; Lenore Asbel; Juli Carlos-Henderson; Roxanne P Kerani; Robert Kohn; Preeti Pathela; Christina Schumacher; Elizabeth A Torrone
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

2.  A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.

Authors:  Cosette M Wheeler; William C Hunt; Jack Cuzick; Erika Langsfeld; Amanda Pearse; George D Montoya; Michael Robertson; Catherine A Shearman; Philip E Castle
Journal:  Int J Cancer       Date:  2012-06-20       Impact factor: 7.396

3.  An Ethical Justification for Expanding the Notion of Effectiveness in Vaccine Post-Market Monitoring: Insights from the HPV Vaccine in Canada.

Authors:  Ana Komparic; Maxwell J Smith; Alison Thompson
Journal:  Public Health Ethics       Date:  2015-01-29       Impact factor: 1.940

4.  Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014.

Authors:  Elaine W Flagg; Elizabeth A Torrone
Journal:  Am J Public Health       Date:  2017-11-21       Impact factor: 9.308

5.  Monitoring the impact of human papillomavirus vaccines on high-grade pre-invasive cervical lesions: designing a framework of linked immunization information system and cancer registry data in Michigan.

Authors:  Rachel C Potter; Elaine W Flagg; S Deblina Datta; Mona Saraiya; Glenn Copeland
Journal:  Vaccine       Date:  2015-01-06       Impact factor: 3.641

6.  Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009.

Authors:  Elaine W Flagg; S Deblina Datta; Mona Saraiya; Elizabeth R Unger; Edward Peters; Lauren Cole; Vivien W Chen; Thomas Tucker; Mary Jane Byrne; Glenn Copeland; Won Silva; Meg Watson; Hillard Weinstock
Journal:  Cancer Causes Control       Date:  2014-02-28       Impact factor: 2.506

7.  Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.

Authors:  Elaine W Flagg; Robert Schwartz; Hillard Weinstock
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

8.  Evaluation of using composite HPV genotyping assay results to monitor human papillomavirus infection burden through simulation.

Authors:  Carol Y Lin
Journal:  BMC Infect Dis       Date:  2015-03-12       Impact factor: 3.090

9.  Monitoring human papillomavirus prevalence in urine samples: a review.

Authors:  Espen Enerly; Cecilia Olofsson; Mari Nygård
Journal:  Clin Epidemiol       Date:  2013-03-12       Impact factor: 4.790

10.  Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction.

Authors:  Claudia Hopenhayn; Amy Christian; Warren Jay Christian; Meg Watson; Elizabeth R Unger; Charles F Lynch; Edward S Peters; Edward J Wilkinson; Youjie Huang; Glenn Copeland; Wendy Cozen; Maria Sibug Saber; Marc T Goodman; Brenda Y Hernandez; Martin Steinau; Christopher Lyu; Thomas T Tucker; Mona Saraiya
Journal:  J Low Genit Tract Dis       Date:  2014-04       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.